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Abstract: Simarteriviruses (Arteriviridae: Simarterivirinae) are commonly found at high titers in the
blood of African monkeys but do not cause overt disease in these hosts. In contrast, simarteriviruses
cause severe disease in Asian macaques upon accidental or experimental transmission. Here, we sought
to better understand the host-dependent drivers of simarterivirus pathogenesis by infecting olive
baboons (n = 4) and rhesus monkeys (n = 4) with the simarterivirus Southwest baboon virus
1 (SWBV-1). Surprisingly, none of the animals in our study showed signs of disease following
SWBV-1 inoculation. Three animals (two rhesus monkeys and one olive baboon) became infected and
sustained high levels of SWBV-1 viremia for the duration of the study. The course of SWBV-1 infection
was highly predictable: plasma viremia peaked between 1 × 107 and 1 × 108 vRNA copies/mL
at 3–10 days post-inoculation, which was followed by a relative nadir and then establishment of
a stable set-point between 1 × 106 and 1 × 107 vRNA copies/mL for the remainder of the study
(56 days). We characterized cellular and antibody responses to SWBV-1 infection in these animals,
demonstrating that macaques and baboons mount similar responses to SWBV-1 infection, yet these
responses are ineffective at clearing SWBV-1 infection. SWBV-1 sequencing revealed the accumulation
of non-synonymous mutations in a region of the genome that corresponds to an immunodominant
epitope in the simarterivirus major envelope glycoprotein GP5, which likely contribute to viral
persistence by enabling escape from host antibodies.
Keywords: Arteriviridae; simarterivirus; SHFV; simian hemorrhagic fever virus; southwest baboon
virus 1; SWBV-1
1. Introduction
Wild non-human primates are an important reservoir of several zoonotic pathogens, and recent
surveys have shown that many harbor microbes with unknown zoonotic potential [1–4]. In particular,
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a high proportion of wild monkeys across sub-Saharan Africa harbor arteriviruses (order: Nidovirales;
family: Arteriviridae) that have a unique genomic architecture (subfamily: Simarterivirinae) [5,6].
In naturally-infected wild African monkeys, simarteriviruses cause persistent high-titer viremia and
exhibit a high degree of intra- and inter-host genetic variation without eliciting any overt signs of
disease—features that may make cross-species transmission to humans more likely [5]. However,
the course of simarterivirus infection in African monkeys, including the acute-phase of infection, is not
well characterized.
Wild Asian macaques (Macaca spp.) are not known to harbor simarteriviruses. However,
captive macaques have been infected with simarteriviruses (both experimentally and unintentionally)
and develop severe and frequently fatal disease characterized by hemorrhage and multi-organ failure,
with lethality often exceeding 50% [7–18]. Indeed, the first two simarteriviruses identified,
simian hemorrhagic encephalitis virus (SHEV) and simian hemorrhagic fever virus (SHFV), were first
encountered in 1964 following two seemingly unconnected outbreaks of viral hemorrhagic fever in
captive macaques at primate facilities in Sukhumi, Georgian SSR, USSR, and the National Institutes
of Health in Bethesda, Maryland, USA, respectively [7]. Since the discovery of these two viruses,
many other outbreaks have occurred in captive Asian macaques throughout the world, with captive
co-housed African monkeys often implicated as the source of infection. Recent retrospective
investigations indicate that many of these outbreaks may have been caused by viruses distinct from
SHEV and SHFV, suggesting that simarteriviruses as a group may be universally pathogenic to
Asian macaques [19]. Of note, not all simarteriviruses are universally fatal in macaques. Crab-eating
macaques (Macaca fascicularis) infected with the simarterivirus Kibale red colobus virus 1 (KRCV-1)
isolated from wild red colobus (Procolobus rufomitratus tephrosceles) in Uganda exhibited mild signs of
disease and fully recovered upon clearance of KRCV-1 viremia [18].
We recently discovered a novel simarterivirus circulating in apparently healthy olive baboons
(Papio anubis) at the Southwest National Primate Research Center (SNPRC) in San Antonio, Texas,
USA, that we termed Southwest baboon virus (SWBV-1, hereafter referred to as “SWBV”) [20].
Using this virus, we sought to understand differences in simarterivirus infection and disease in
natural (i.e., baboon) versus non-natural (i.e., macaque) hosts that are 98% genetically identical.
In this study, we have the broader goal of understanding host factors that facilitate or protect against
the development of viral hemorrhagic fever. Concurrently, a similar study was conducted in patas
monkeys (Erythrocebus patas) and rhesus monkeys (Macaca mulatta) using SHFV (see article by
Cornish et al., currently under review).
2. Materials and Methods
2.1. Study Design
The experimental design and protocols were agreed upon prior to initiation of the study and were
not modified after the study had begun. Animal care, observations, and clinical laboratory testing were
performed at the Southwest National Primate Research Center (SNPRC) in San Antonio, Texas, USA.
Viral loads, flow cytometry, and data analysis were performed in batch at the Wisconsin National
Primate Research Center (WNPRC), Madison, Wisconsin, USA, after conclusion of the study.
2.2. Care and Ethical Use of Animals
All baboons and macaques used in this study were cared for by the staff at the Southwest National
Primate Research Center in accordance with the regulations and guidelines outlined in the Animal
Welfare Act and the Guide for the Care and Use of Laboratory Animals. Details of this study (protocol
1539 PC, MM 0) were approved by the Texas Biomedical Research Institute’s Animal Care and Use
Committee in November of 2016, in accordance with recommendations of the Weatherall Report.
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2.3. Clinical Scoring
Animals were observed for signs of disease and scored according to the parameters
described below. Scores equal to or greater than 5 required evaluation by the study veterinarian.
Scores equal to or greater than 15 were deemed terminally ill. Weight loss: 0 = decrease of 0–10%;
1 = decrease of 10–20%; 2 = decrease of ≥20%. Temperature: 0 = change <2 ◦F; 1 = change of 2–3 ◦F;
2 = change of 3–4 ◦F; 3 = change of≥5 ◦F. Responsiveness: 0 = alert, responsive, normal activity, free of
disease signs or exhibits only resolved/resolving disease signs; 1 = slightly diminished general activity,
subdued but responds normally to external stimuli; 2 = withdrawn, may have head down, fetal posture,
hunched, reduced response to external stimuli; 8 = prostrate but able to rise if stimulated, moderate to
dramatically reduced response to external stimuli; 15 = persistently prostrate, severely or completely
unresponsive, may have signs of respiratory distress. Hair coat: 0 = normal appearance; 1 = rough
hair coat. Respiration: 0 = normal breathing; 3 = labored; 15 = agonal. Petechia: 0 = none; 1 = mild
(1–39%); 2 = moderate (40–79%); 3 = severe (≥80%). Bleeding: 0 = none; 1 = at bleeding site; 2 = other
than bleeding site. Nasal discharge: 0 = not present; 1 = present. Chow eaten: 0 = 25–100%; 1 = <25%.
Food enrichment: 0 = 25–100%; 1 = <25%. Stool: 0 = normal; 1 = no stool present; 2 = diarrhea.
Fluid Intake: 0 = drinking normal amounts; 1 = reduced fluid intake; 2 = no intake. Skin tenting:
0 = normal, 1 = ≥2 s.
2.4. Virus Inoculations
A SWBV stock was created for this study by aliquoting plasma collected from olive baboon 15290,
which was found to be viremic with SWBV via RT-qPCR during a screen of 30 baboons at SNPRC.
Macaques and baboons infected with SWBV in this study were inoculated intramuscularly with 500
µL of plasma from this animal containing 1.7 × 105 vRNA copies of SWBV.
2.5. Deep Sequencing
Samples were processed for sequencing in a biosafety level 3 laboratory. For each animal, viral
RNA was isolated from approximately 200 µL of plasma using the Qiagen QIAamp MinElute virus
spin kit (Qiagen, Hilden, Germany), omitting carrier RNA. cDNA synthesis and PCR were performed
using random hexamers (for the inoculum) or with seven primer sets (for the remaining animals,
see Table S2) to amplify the entire SWBV genome in overlapping amplicons with the Superscript III
One-Step RT-PCR kit with Platinum Taq Polymerase (Invitrogen, Carlsbad, CA, USA). All amplicons
from a single sample were pooled to achieve 1 ng of total amplified DNA in 5 µL. Pooled amplicons
(or total cDNA generated from random-hexamer amplification) were fragmented, and sequencing
adaptors were added using the Nextera XT DNA Library Preparation Kit (Illumina, San Diego,
CA, USA). Indexed sequencing libraries were cleaned using AMPure XP beads (Agencourt Bioscience
Corporation, Beverly, MA, USA) and quantified using the Qubit dsDNA HS Assay Kit with the Qubit
fluorometer (Invitrogen, Carlsbad, CA, USA). Product length was measured using the Agilent 2100
Bioanalyzer High Sensitivity DNA kit (Life Technologies, Madison, WI, USA). Deep sequencing was
performed on the Illumina MiSeq. Sequencing of SWBV from baboon 15290 was performed in 2016;
all other sequencing was performed on the same MiSeq run in 2018. SWBV sequencing reads pertaining
to this study can be found online [21].
2.6. Sequence Read Mapping and Variant Calling
Raw sequencing reads from baboon 15290 (the inoculum) were mapped to the
previously-published SWBV-1 sequence (GenBank #KM110947) to generate an inoculum consensus
sequence (GenBank #MH686150). Annotations were then transferred from KM110947 to MH686150
and checked manually. For baboon 31459 (12 days post-inoculation (DPI)), macaque 31721 (56 DPI),
and macaque 31816 (56 DPI), reads were mapped to each of the seven amplicons individually. Ten
thousand mapped reads were randomly subsampled from each amplicon in each sample, normalizing
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coverage at approximately 1000× per nucleotide site throughout the complete genome. The normalized
reads were then mapped to the consensus sequence of the inoculum using the bbmap read mapper [22].
Minor variants that comprise at least 5% of total sequences in any of the four samples were identified
using the bbmap callvariants.sh tool. The predicted effect of these variants on SWBV was calculated
using snpEff [23] (Table S1). These sequencing datasets and Jupyter notebooks that create the data
analysis environment and reproducibly perform the data analyses can be downloaded [24].
2.7. Viral Loads
A TaqMan RT-qPCR assay was developed to quantify SWBV-1 plasma viral RNA (forward primer:
5’-GCTTGCTGGTAAGATTGCCA-3’; reverse primer: 5’-GCAGCGGATCTTTGTGGAA-3’; probe:
5’-6FAM-TGATTAACCTGAGGAAGTATGGCTGGC-BHQ1-3’), as described in detail previously [20].
Briefly, RNA was extracted from 100 µL of plasma using the Viral Total Nucleic Acid Purification
Kit (Promega, Madison, WI, USA) on a Maxwell 16 MDx instrument and eluted in 50 µL.
Reverse transcription and PCR were performed using the SuperScript III One-Step qRT-PCR
system (Invitrogen, Carlsbad, CA, USA) on a LightCycler 480 (Roche, Indianapolis, IN, USA).
Reverse transcription was carried out at 37 ◦C for 15 min and then 50 ◦C for 30 min followed by
2 min at 95 ◦C and then 50 cycles of amplification as follows: 95 ◦C for 15 s and 60 ◦C for 1 min.
The 50 µL-reaction mixture contained 5 µL of extracted RNA, MgSO4 at a final concentration of 3.0 mM,
with the two amplification primers at a concentration of 500 nM and probe at a concentration of 100 nM.
RNA copy numbers were calculated using a standard curve (described previously in [20]) that was
sensitive down to 10 copies of RNA transcript per reaction.
2.8. Peptide Array
Viral protein sequences were selected and submitted to Roche Sequencing Solutions (Madison, WI,
USA) for development into a peptide microarray as part of an early access program. Protein sequences
were predicted from the SWBV inoculum nucleotide sequence, and 16-mer peptides tiling each protein
were designed to span each viral protein with a step size of 1 (amino acid overlap of 15). The peptide
sequences were synthesized in situ with a Roche Sequencing Solutions Maskless Array Synthesizer
(MAS) by light-directed solid-phase peptide synthesis using an amino-functionalized plastic support
(Greiner Bio-One, Kremsmünster, Austria) coupled with a 6-aminohexanoic acid linker and amino
acid derivatives carrying a photosensitive 2-(2-nitrophenyl) propyloxycarbonyl (NPPOC) protection
group (Orgentis Chemicals, Gatersleben, Germany). To reduce instrument variance, each peptide was
printed at 5 locations on the array. Samples were diluted 1:100 in binding buffer (0.01 M Tris-Cl, pH 7.4,
1% alkali-soluble casein, 0.05% Tween-20). Diluted sample aliquots and negative controls containing
binding buffer only were bound to arrays overnight at 4 ◦C. After binding, the arrays were washed 3×
in wash buffer (1 × TBS, 0.05% Tween-20), 10 min per wash. Primary sample binding was detected via
8F1-biotin mouse anti-primate IgG (NIH nonhuman primate reagent resource) secondary antibody.
The secondary antibody was diluted 1:10,000 (final concentration 0.1 ng/µL) in secondary binding
buffer (1 × TBS, 1% alkali-soluble casein, 0.05% Tween-20), incubated with arrays for 3 h at room
temperature, and then washed 3× in wash buffer (10 min per wash) and in reagent-grade water for
30 s. The secondary antibody was labeled with Cy5-Streptavidin (GE Healthcare; 5 ng/µL in 0.5× TBS,
1% alkali-soluble casein, 0.05% Tween-20) for 1 h at room temperature, and then the array was washed
2× for 1 min in 1 × TBS and washed once for 30 s in reagent-grade water. The fluorescent signal of the
secondary antibody was detected by scanning at 635 nm at 2 µm resolution and 25% gain, using an
MS200 microarray scanner (Roche NimbleGen, Madison, WI, USA). The raw fluorescence signal
intensity values were log2 transformed, and the median transformed intensity of the redundant amino
acid peptides was determined. Next, background subtraction was performed using the blank samples
as background reactivity. Fold change from 0 DPI was calculated by subtracting the respective 0 DPI
reactivity on a per amino acid peptide and per animal basis. The peptide array datasets and Jupyter
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notebooks that create the data analysis environment and reproducibly perform the data analyses can
be downloaded [24].
2.9. Flow Cytometry
Cryopreserved peripheral blood mononuclear cells (PBMCs) were thawed at 37◦C and washed in
R10 media (RPMI containing 10% fetal bovine serum (FBS)). Between 3–5 million washed cells were
transferred to 1.2 mL-cluster tubes and resuspended in phosphate-buffered saline (PBS) supplemented
with 10% FBS containing fluorescence-activated cell sorting (FACS) buffer. Cells were stained at
37 ◦C with a mastermix of antibodies against CD38 (clone AT1, FITC conjugate, 20 µL), CD3 (clone
SP34-2, Alexa Fluor 700 conjugate, 3 µL), CD8 (clone SK1, Brilliant Violet 510 conjugate, 2.5 µL), CD20
(clone 2H7, Brilliant Violet 650 conjugate, 2 µL), and CD4 (clone L200, Brilliant Violet 711 conjugate,
5 µL) antigens. All antibodies were obtained from BD BioSciences (San Jose, CA, USA), except the
CD38-specific antibody, which was purchased from Stemcell Technologies (Vancouver, BC, Canada).
Cells were also stained with LIVE/DEAD Fixable Near-IR during this time (Invitrogen, Carlsbad, CA).
Cells were washed twice with FACS buffer and fixed with 0.125 mL of 2% paraformaldehyde for
20 min. After an additional wash, the cells were permeabilized using Bulk Permeabilization Reagent
from Invitrogen (Carlsbad, CA, USA). The cells were stained for 15 min with an antibody against Ki67
(clone B56, Alexa Fluor 647 conjugate, 5 µL) in the presence of permeabilizer. The cells were then
washed twice and resuspended in 0.125 mL of 2% paraformaldehyde for an additional 20 min. After a
final wash and resuspension with 0.125 mL of FACS buffer, all samples were run on a BD LSRII Flow
Cytometer within 24 h. Flow data were analyzed using Flowjo version 9.8.2.
2.10. Statistical Analysis
Information on statistical tests used to determine significance can be found in corresponding
figure legends. All statistical analyses except those involving sequence analysis and peptide array
analysis were performed using Prism7 (GraphPad Software, La Jolla, CA).
2.11. Data Accessibility
The sequence of the SWBV-1 inoculum used in this study can be found in GenBank
(#MH686150). SWBV sequencing reads pertaining to this study can be found online at [21] under
submission SRP155732 containing the accessions: SAMN09729057, SAMN09729058, SAMN09729059,
and SAMN09729060. The workflow used to perform sequence analysis can be found at [24].
3. Results
3.1. Prevalence of SWBV Infection at SNPRC and Selection of SWBV-Naïve Baboons
To further define the prevalence of SWBV infection in baboons at SNPRC, we screened
blood collected from 30 random baboons—19 olive baboons (Papio Anubis); 10 olive-yellow (Papio
cynocephalus) hybrid baboons; and 1 hamadryas-olive (Papio hamadryas) hybrid baboon—as well
as 6 former olive baboon cage-mates of two olive baboons known to be SWBV-infected using a
SWBV-specific qRT-PCR assay described previously. Of these animals, only one olive baboon (a former
cage-mate), baboon 15290, had SWBV RNA detectable in its blood at a titer of 3.4 × 105 vRNA
copies/mL of plasma, for a prevalence of roughly 3% (Figure 1A,B). Unbiased deep sequencing of this
specimen did not result in the identification of any other potential pathogens [20]. To minimize the
likelihood of prior SWBV infection, we selected four adult male baboons from the specific-pathogen free
(SPF) colony at SNPRC. These animals had tested negative for a variety of common primate pathogens,
were brought into the SPF colony as infants, and reared separately from the general colony.
These baboons also tested negative for SWBV infection by qRT-PCR.
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rubric. At no time-point did any animal become clinically ill (score ≥5), nor were significant 
differences between SWBV-infected and uninfected animals noted (Figure 2A). This result is in stark 
contrast to past studies of SHEV or SHFV infection in crab-eating macaques, stump-tailed macaques, 
and rhesus monkeys, which resulted in extremely high morbidity and mortality (Figure 2B). No 
significant changes from baseline vital signs, or vital sign differences between SWBV-infected and 
uninfected animals of either species were observed (Figure 2C). 
Figure 1. Infection of baboons and macaques with SWBV. (A) Thirty-six baboons from the
specific-pathogen free (SPF) colony at SNPRC were screened for SWBV infection using qRT-PCR.
(B) This screening identified one SWBV+ baboon. Serum from this animal was used to inoculate
(C) macaques (solid symbols with solid lines) and (D) baboons (open symbols with dashed lines),
resulting in productive infection (red) or no infection (black) for animals from each species. Note:
coloring and symbols denoting species, animal ID, and infection-status are used consistently throughout
the manuscript. (E) The average course of SWBV viremia from all infected animals is in dark red,
with the standard error of the mean shown in lighter red.
3.2. The Course of SWBV Infection in Baboons and Macaques
To study differences in SWBV infection between baboons and macaques, we inoculated
four olive baboons (Papio anubis, hereafter referred to as “baboons”) and four rhesus monkeys
(Macaca mulatta, hereafter referred to as “macaques”) intramuscularly with 500 µL of serum from
baboon 15290 containing 1.7 × 105 vRNA copies of SWBV and quantified viremia using qRT-PCR
(Figure 1C,D). Five animals (two macaques and three baboons) had no detectable SWBV viremia
at any time point. Three animals (two macaques and one baboon) became productively infected.
Among the infected animals, the course of SWBV infection was highly predictable: plasma viremia
peaked between 1 × 107 and 1 × 108 vRNA copies/mL at 3–10 DPI, followed by a relative nadir
and then establishment of a stable set-point between 1 × 106 and 1 × 107 vRNA copies/mL for the
remainder of the study (56 d) (Figure 1E).
3.3. SWBV Does not Cause Overt Disease in Baboons or Macaques
We closely monitored all animals for signs of disease using a comprehensive clinical scoring rubric.
At no time-point did any animal become clinically ill (score ≥5), nor were significant differences
between SWBV-infected and uninfected animals noted (Figure 2A). This result is in stark contrast
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to past studies of SHEV or SHFV infection in crab-eating macaques, stump-tailed macaques,
and rhesus monkeys, which resulted in extremely high morbidity and mortality (Figure 2B).
No significant changes from baseline vital signs, or vital sign differences between SWBV-infected and
uninfected animals of either species were observed (Figure 2C).Viruses 2018, 10, x FOR PEER REVIEW  7 of 16 
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partial thromboplastin time (PTT) (Figure 3B). Blood concentrations of creatinine, aspartate 
aminotransferase, and alanine aminotransferase—which serve as markers of kidney function and 
liver cell death, respectively—were not significantly different between SWBV-infected and 
Figure 2. Clinical evaluation of baboons and macaques inoculated with SWBV. (A) Animals were
evaluated for signs of disease twice per day using a comprehensive clinical scoring rubric in which a
score of <5 was deemed within normal limits. (B) For macaques, mortality was also assessed (black line)
and compared to previous studies of simarterivirus infection in macaques (corresponding references in
italics); the virus and hosts for the simarteriviruses shown are found below the graph in parentheses
(SHFV has an asterisk because the natural host is not known and the sequence identity of the viruses
used in some of these studies has never been confirmed). Vital signs for baboons and macaques are
shown in (C). Macaques are shown as solid symbols with solid lines, baboons are shown as open
symbols with dashed lines; infected animals are shown in red and uninfected animals are shown
in black.
To examine more sensitive markers of infection, inflammation, and organ dysfunction,
we performed a battery of laboratory tests on each animal over the course of the study, the most
pertinent of which are shown (Figure 3). No significant changes in white blood cell counts or the
numbers of leukocyte subsets were seen over the course of the experiment for either SWBV-infected
or uninfected animals (Figure 3A). Additionally, in stark contrast to previous studies of SHFV
in macaques, no coagulation abnormalities were observed for any of the animals, as measured by blood
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concentrations of fibrinogen or functional clotting assays, including pro-thrombin time (PT) and partial
thromboplastin time (PTT) (Figure 3B). Blood concentrations of creatinine, aspartate aminotransferase,
and alanine aminotransferase—which serve as markers of kidney function and liver cell death,
respectively—were not significantly different between SWBV-infected and uninfected animals
(Figure 3C). Finally, necropsies performed at 56 DPI revealed no gross or microscopic differences
between SWBV-infected and uninfected animals.
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dashed lines; infected animals are shown in red and uninfected animals are shown in black.
3.4. Arterivirus-Specific Adaptive Immune Responses in SWBV-Infected Macaques and Baboons
To evaluate immune responses to SWBV, we assessed immune-cell activation in peripheral blood
mononuclear cells (PBMC) from SWBV-inoculated baboons and macaques using flow cytometry
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(Figure 4A). No significant deviations from baseline levels of CD4+ T cell, CD8+ T cell, or natural killer
(NK) cell activation were observed in uninfected animals (Figure 4B). However, the percentage of
activated CD4+ T cells, CD8+ T cells, and NK cells increased substantially in animals that became
SWBV-viremic (Figure 4B): In macaque 31721 and baboon 31459, the percentage of activated immune
cells peaked at 10 DPI and then quickly returned to near-baseline levels; activation of these immune-cell
subsets peaked later in macaque 31816 (between d 14 and 21) with the proportion of activated CD8+ T
cells remaining elevated through 56 DPI.
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We also assessed antibody responses to SWBV using a microarray of 16-mer peptides that spanned
the SWBV proteome with a one amino acid offset. Many arterivirus envelope glycoproteins are
predicted to have relatively unstructured proteins and have been shown to elicit antibodies that
recognize linear epitopes, suggesting that many of the antibodies identified by this approach would be
functional [25]. No SWBV-specific antibodies were detected at levels above background in any animals
that were aviremic throughout the study (Figure 5A). In SWBV-infected animals, SWBV-specific
antibodies became detectable between 12 and 28 DPI. Although multiple envelope glycoproteins were
targeted by antibodies in each of the SWBV-infected animals, common responses were focused against
glycoproteins 5 and 6 (GP5 and GP6), with the most robust responses generated to GP5 (Figure 5B).
In particular, two distinct regions/epitopes of GP5, corresponding to amino acids 28–62 and 76–111,
were targeted, with the macaques mounting more robust responses to GP528–62 and the baboon
mounting a more robust response to GP576–111. Multiple attempts to propagate SWBV on cultured
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primary and immortalized cells were unsuccessful, preventing further functional characterization of
these antibody responses.
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Figure 5. Peptide array analysis of antibodies generated by baboons and macaques inoculated with 
SWBV. A custom-designed array of 16-mer peptides spanning each of the SWBV proteins predicted from the 
SWBV inoculum nucleotide sequence was constructed and plasma from SWBV-infected animals was overlaid on 
this array to identify SWBV-specic antibodies. (A) Intensity of antibodies binding to peptides corresponding to 
the envelope glycoproteins of SWBV, normalized to the day zero post-inoculation intensity for each peptide from 
each animal, with day zero shown in blue and subsequent days shown in increasing shades of red. Note, numbers 
on the X-axis correspond to the rst amino acid in the 16-mer peptide. (B) Normalized intensities over time from 
the GP5 protein of the three animals that became infected with SWBV; the graph to the right shows the mean fold 
change from day zero post-inoculation for all GP5 peptides, with SWBV-infected animals shown in red. 
i r 5. Peptide arr y analysis of antibodi s generated by baboons and macaques inoculated
with SWBV. A custom-designed array of 16-mer peptides spanning each of the SWBV proteins predicted
from the SWBV inoculum nucleotide sequence was constructed, and plasma from SWBV-infected
animals was overlaid on this array to id ntify SWBV-specific antibodies. (A) Intensity of antibodies
binding to peptides corresponding to the envelope glycoproteins of SWBV, normalized to the day 0
post-inoculation intensity for each peptide from each animal, with day 0 shown in blue and subsequent
days shown in increasing shades of red. Note, numbers on the X-axis correspond to the first amino
acid in the 16-mer peptide. (B) Normalized intensities over time from the GP5 protein of the three
animals that became infected with SWBV; the graph to the right shows the mean fold change from day
0 post-inoculation for all GP5 peptides, with SWBV-infected animals shown in red.
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3.5. Intra-Host Evolution of SWBV over the Course of Infection
We examined the genetic changes in SWBV that accumulated over the course of each animal’s
infection by performing deep sequencing on plasma collected from each viremic animal. Compared to
the virus used for inoculation, we found mutations in nearly every SWBV gene (Table S1), many of
which were not present at detectable levels in the inoculum. However, the density of non-synonymous
mutations was not evenly distributed, with many mutations occurring in the genes encoding envelope
glycoproteins, particularly the GP5-encoding ORF5 gene.
4. Discussion
In this study, we attempted to infect baboons and macaques with a baboon arterivirus,
SWBV, to more fully characterize the pathogenesis of simarterivirus infection in natural versus
non-natural hosts. Given the history of simarteriviruses causing severe disease in macaques,
we expected macaques infected with SWBV to develop significant disease. Surprisingly, however,
SWBV resulted in clinically unapparent disease in macaques, despite high-titer and persistent viremia.
While high-titer and persistent viremia is likely the most common course of simarterivirus infection in
naturally infected African monkeys [5], this finding is (to our knowledge) the first example of persistent
simarterivirus infection in macaques. The lack of disease observed in this study is in contrast to the
cotemporaneous study performed by Cornish et al., in which patas monkeys and rhesus monkeys
both developed laboratory aberrations and physical signs of disease following infection with SHFV.
Therefore, simarterivirus infections appears to be: 1) sub-clinical in African monkeys [6,20,26–29],
2) pathogenic in African monkeys [30–32] and Cornish et al., 3) sub-clinical in Asian-origin macaques
(this study), and 4) pathogenic in Asian-origin macaques [7–18]. The viral factors that that render
some simarteriviruses (e.g., SWBV) non-pathogenic but confer virulence to other simarteriviruses (e.g.,
SHFV) remain to be defined, but clearly cannot be explained by host differences alone.
Analysis of immune responses to SWBV and SHFV provided no additional explanation for the
range of disease observed in this study and the study by Cornish et al. In this study, SWBV infection
persisted in all three animals that became infected despite SWBV-specific immune responses.
Antibody responses to SWBV primarily were directed against the major envelope glycoprotein, GP5.
More specifically, antibodies were raised against two N-terminal epitopes in GP5 corresponding to
amino acids 28–62 and 76–111. Although the relative strength of these responses differed between
the macaques and the baboon, with antibodies to the epitope corresponding to amino acids 28–62
dominating in the macaques and antibodies to the epitope corresponding to amino acids 76–111
dominating in the baboon, none of these responses were capable of achieving viral clearance. Antibody
responses to the other arteriviruses have also been mapped to two N-terminal epitopes in GP5 [33–36].
Intriguingly, the more N-terminal of these two epitopes in porcine reproductive and respiratory
syndrome virus (PRRSV) is immunodominant but elicits a non-neutralizing response, referred to
by some as a “decoy epitope” [37]. A similar mechanism of immune evasion may be employed by
simarteriviruses. Indeed, we identified amino acid changes in these epitopes—including mutations in
predicted glycosylation sites—that would presumably abrogate antibody binding and allow SWBV
to establish persistent infection by escaping antibody responses. Interestingly, the vast majority of
non-synonymous mutations in the viruses from these animals are found in the sequence corresponding
to the more C-terminal epitope (GP5 amino acids 76–111), further suggesting that antibodies to the
more N-terminal epitope (GP5 amino acids 28–62) are non-neutralizing and do not exert a significant
selective pressure on the virus (Figure 6). This also suggests that antibodies to the C-terminal epitope
exert a stronger selection pressure on the virus, potentially implicating this epitope as a target of
neutralizing antibodies, similar to what has been observed in other arteriviruses.
Viruses 2018, 10, 701 12 of 15
Macaque 31721
Non-synonymous sequence change:
Amino acid position: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 10
0
10
1
10
2
10
3
10
4
10
5
10
6
10
7
10
8
10
9
11
0
11
1
11
2
11
3
11
4
11
5
11
6
11
7
11
8
11
9
12
0
12
1
12
2
12
3
12
4
12
5
12
6
12
7
Amino acid: M N K C Y R N W A P S L M P S L S T S F L C T F L L L F T C L S P S A A N N T S Y G P Q K V L S G I F S N L F S P S Y V V N I S V C G A F D I Q N N T H W F R P C N V S Q L Q N A T K N A T D E A H I K S L P C V I H N Y T G T H I N H T K V L L E T Y L A V
 0-1 0%
 1-2 10%
 2-3 20%
 3-4 30%
 4-5 40%
 5-6 50%
 6-7 60%
 7-8 70%
80%
90%
Macaque 31816 100%
Non-synonymous sequence change:
Amino acid position: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 10
0
10
1
10
2
10
3
10
4
10
5
10
6
10
7
10
8
10
9
11
0
11
1
11
2
11
3
11
4
11
5
11
6
11
7
11
8
11
9
12
0
12
1
12
2
12
3
12
4
12
5
12
6
12
7
Amino acid: M N K C Y R N W A P S L M P S L S T S F L C T F L L L F T C L S P S A A N N T S Y G P Q K V L S G I F S N L F S P S Y V V N I S V C G A F D I Q N N T H W F R P C N V S Q L Q N A T K N A T D E A H I K S L P C V I H N Y T G T H I N H T K V L L E T Y L A V Putative glycosylation
Baboon 31459
Non-synonymous sequence change:
Amino acid position: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 10
0
10
1
10
2
10
3
10
4
10
5
10
6
10
7
10
8
10
9
11
0
11
1
11
2
11
3
11
4
11
5
11
6
11
7
11
8
11
9
12
0
12
1
12
2
12
3
12
4
12
5
12
6
12
7
Amino acid: M N K C Y R N W A P S L M P S L S T S F L C T F L L L F T C L S P S A A N N T S Y G P Q K V L S G I F S N L F S P S Y V V N I S V C G A F D I Q N N T H W F R P C N V S Q L Q N A T K N A T D E A H I K S L P C V I H N Y T G T H I N H T K V L L E T Y L A V
Signal 
intensity for 
each 
peptide 
Percentage 
of seq reads 
containing 
non-syn  
variant
Figure 6. Correlation of SWBV mutations with antibody responses. Antibody binding intensity data (see Figure 5) are shown for each peptide covering the region of
interest in GP5 as a heat-mapped scale of 0 (white) to >7 (black). Overlaid are the non-synonymous sequencing changes corresponding to each amino acid of GP5
(see Table S1), with a heat-map highlighting variants contained in 20% (pink) to 100% (dark red) of deep sequencing reads. Amino acids in green highlight residues
with predicted N-linked glycosylation. Data for each animal correspond to analysis of the day 56 post-inoculation time-point with the exception of sequencing data
from baboon 31459, for which day 12 post-inoculation.
Viruses 2018, 10, 701 13 of 15
The majority of animals in this study (5/8) did not become infected upon inoculation with SWBV.
This finding seems unlikely to be due to pre-existing immunity from a prior SWBV infection.
Pre-existing immunity would have presumably resulted in detectable anti-SWBV antibodies and/or
robust proliferation of immune cells following SWBV inoculation—neither of which were seen.
Immunity due to prior or ongoing infection with a different simarterivirus is also unlikely,
as heterologous protection between divergent simarterivirus strains is not seen [18]. A technical
error in the inoculation process is also possible but unlikely, considering that animals in each group
were successfully infected. SWBV also replicated to high titers in animals that became viremic,
arguing against the potential that SWBV was poorly adapted to replication in the baboon or
macaque host. Therefore, it is possible that the uninfected animals were innately resistant to
simarterivirus infection, or that we used a dose of SWBV (1.7 × 105 vRNA copies) that only infects
50% of animals (~1 infectious dose 50% (ID50)).
Several parallels can be drawn between the simarteriviruses and simian immunodeficiency
viruses (SIVs): both naturally infect monkeys throughout sub-Saharan Africa and have variable
propensities for causing disease upon transmission to non-natural primate hosts. Cross-species
transmission of SIVs to humans and other great apes has had devastating consequences (e.g.,
the global HIV-1-pandemic), but not all SIVs have the same potential for infecting and causing disease
in humans. By analogy, the consequences of simarterivirus infection in humans remains unknown,
and different simarteriviruses may have different propensities for infecting and causing disease in
humans [5]. If macaques are the best proxy for assessing such variables (as they are in the case of
SIV/HIV), then it is possible that simarteriviruses are capable of causing a range of disease in humans,
including asymptomatic infection. Consequently, we believe that simarterivirus research should be
intensified to allow an appropriate risk assessment.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/10/12/701/
s1, Figure S1: Flow cytometry gating strategy; Table S1: Single nucleotide variants found at >5% in SWBV from
infected animals; Table S2: Primers used for amplicon sequencing of SWBV.
Author Contributions: Conceptualization, A.L.B., J.H.K, and D.H.O.; methodology, A.L.B and C.B.; software,
D.A.B.; formal analysis, A.L.B, C.B., M.S., and D.A.B.; investigation, A.L.B, C.B., M.S., C.N., D.C., B.G., K.B., and
D.A.B.; writing—original draft preparation, A.L.B and C.B.; writing—review and editing, J.H.K, R.F.J., J.P.C.,
D.H.O., and R.L.
Funding: This investigation was supported by a Pilot Grant from the Southwest National Primate Research Center
grant P51OD011133 from the Office of Research Infrastructure Programs (ORIP), National Institutes of Health.
This work was also made possible by funding to the Wisconsin National Primate Research Center (P51RR000167)
from ORIP. This research was conducted in part at a facility constructed with support from Research Facilities
Improvement Program grant numbers RR15459-01 and RR020141-01. A.L.B. performed this work with support
from the University of Wisconsin–Madison’s Medical Scientist Training Program (MSTP) (grant T32GM008692)
and the Physician Scientist Training Program (PSTP) sponsored by the Department of Pathology and Immunology
at Washington University in St. Louis School of Medicine. The authors thank the University of Wisconsin,
Department of Pathology and Laboratory Medicine and the WNPRC for funding and the use of its facilities and
services. This work was also funded in part through the National Institute of Allergy and Infectious Diseases
(NIAID) Division of Intramural Research (J.P.C. and R.F.J.) and the Battelle Memorial Institute’s prime contract
with the US NIAID under Contract No. HHSN272200700016I (J.H.K.). This publication’s contents are solely the
responsibility of the author(s) and do not necessarily represent the official views of ORIP, of ORIP, the US National
Institutes of Health, NIAID, US Department of Health and Human Services, or of the institutions and companies
affiliated with the authors. The funders of this research had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript. All authors edited and approved the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Davies, T.J.; Pedersen, A.B. Phylogeny and geography predict pathogen community similarity in wild
primates and humans. Proc. Biol. Sci. R. Soc. 2008, 275, 1695–1701. [CrossRef] [PubMed]
2. Cooper, N.; Nunn, C.L. Identifying future zoonotic disease threats: Where are the gaps in our understanding
of primate infectious diseases? Evol. Med. Public Health 2013, 2013, 27–36. [CrossRef] [PubMed]
Viruses 2018, 10, 701 14 of 15
3. Calvignac Spencer, S.; Leendertz, S.A.J.; Gillespie, T.R.; Leendertz, F.H. Wild great apes as sentinels and
sources of infectious disease. Clin. Microbiol. Infect. 2012, 18, 521–527. [CrossRef] [PubMed]
4. Hoppe, E.; Pauly, M.; Gillespie, T.R.; Akoua-Koffi, C.; Hohmann, G.; Fruth, B.; Karhemere, S.; Madinda, N.F.;
Mugisha, L.; Muyembe, J.-J. Multiple cross-species transmission events of human adenoviruses (HAdV)
during hominine evolution. Mol. Biol. Evol. 2015, 8, 2072–2084. [CrossRef] [PubMed]
5. Bailey, A.L.; Lauck, M.; Sibley, S.D.; Friedrich, T.C.; Kuhn, J.H.; Freimer, N.B.; Jasinska, A.J.;
Phillips-Conroy, J.E.; Jolly, C.J.; Marx, P.A.; et al. Zoonotic Potential of Simian Arteriviruses. J. Virol.
2015, 90, 630–635. [CrossRef] [PubMed]
6. Bailey, A.L.; Lauck, M.; Ghai, R.R.; Nelson, C.W.; Heimbruch, K.; Hughes, A.L.; Goldberg, T.L.; Kuhn, J.H.;
Jasinska, A.J.; Freimer, N.B. Arteriviruses, pegiviruses, and lentiviruses are common among wild African
monkeys. J. Virol. 2016, 15, 6724–6737. [CrossRef] [PubMed]
7. Palmer, A.E.; Allen, A.M.; Tauraso, N.M.; Shelokov, A. Simian hemorrhagic fever. I. Clinical and
epizootiologic aspects of an outbreak among quarantined monkeys. Am. J. Trop. Med. Hyg. 1968, 17,
404–412. [CrossRef] [PubMed]
8. Allen, A.M.; Palmer, A.E.; Tauraso, N.M.; Shelokov, A. Simian hemorrhagic fever. II. Studies in pathology.
Am. J. Trop. Med. Hyg. 1968, 17, 413–421. [CrossRef]
9. Tauraso, N.M.; Shelokov, A.; Palmer, A.E.; Allen, A.M. Simian hemorrhagic fever. III. Isolation and
characterization of a viral agent. Am. J. Trop. Med. Hyg. 1968, 17, 422–431. [CrossRef]
10. Lapin, B.A.; Pekerman, S.M.; Iakovleva, L.A.; Dzhikidze, E.K.; Shevtsova, Z.V.; Kuksova, M.I.; Dan’ko, L.V.;
Krylova, R.I.; Akbroit, E.I.; Agrba, V.Z. Hemorrhagic fever in monkeys. Vopr. Virusol. 1967, 12, 168–173.
11. Espana, C. Review of some outbreaks of viral disease in captive nonhuman primates. Lab. Anim. Sci. 1971,
21, 1023–1031. [PubMed]
12. Abildgaard, C.; Harrison, J.; Espana, C.; Spangler, W.; Gribble, D. Simian hemorrhagic fever: Studies of
coagulation and pathology. Am. J. Trop. Med. Hyg. 1975, 24, 537–544. [CrossRef] [PubMed]
13. London, W.T. Epizootiology, transmission and approach to prevention of fatal simian haemorrhagic fever in
rhesus monkeys. Nature 1977, 268, 344–345. [CrossRef] [PubMed]
14. Renquist, D. Outbreak of simian hemorrhagic fever. J. Med. Primatol. 1990, 19, 77–79. [PubMed]
15. Dalgard, D.W.; Hardy, R.J.; Pearson, S.L.; Pucak, G.J.; Quander, R.V.; Zack, P.M.; Peters, C.J.; Jahrling, P.B.
Combined simian hemorrhagic fever and Ebola virus infection in cynomolgus monkeys. Lab. Anim. Sci.
1992, 42, 152–157. [PubMed]
16. Johnson, R.F.; Dodd, L.E.; Yellayi, S.; Gu, W.; Cann, J.A.; Jett, C.; Bernbaum, J.G.; Ragland, D.R.; St Claire, M.;
Byrum, R.; et al. Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic
fever: Clinical characterization and risk factors for severe disease. Virology 2011, 421, 129–140. [CrossRef]
17. Vatter, H.A.; Donaldson, E.F.; Huynh, J.; Rawlings, S.; Manoharan, M.; Legasse, A.; Planer, S.; Dickerson, M.F.;
Lewis, A.D.; Colgin, L.M.; et al. A simian hemorrhagic fever virus isolate from persistently infected baboons
efficiently induces hemorrhagic fever disease in Japanese macaques. Virology 2015, 474, 186–198. [CrossRef]
18. Wahl-Jensen, V.; Johnson, J.C.; Lauck, M.; Weinfurter, J.T.; Moncla, L.H.; Weiler, A.M.; Charlier, O.; Rojas, O.;
Byrum, R.; Ragland, D.R.; et al. Divergent Simian Arteriviruses Cause Simian Hemorrhagic Fever of Differing
Severities in Macaques. MBio 2016, 7, e02009-15. [CrossRef]
19. Lauck, M.; Alkhovsky, S.V.; Bào, Y.M.; Bailey, A.L.; Shevtsova, Z.V.; Shchetinin, A.M.; Vishnevskaya, T.V.;
Lackemeyer, M.G.; Postnikova, E.; Mazur, S.; et al. Historical Outbreaks of Simian Hemorrhagic Fever in
Captive Macaques Were Caused by Distinct Arteriviruses. J. Virol. 2015, 15, 8082–8087. [CrossRef]
20. Bailey, A.L.; Lauck, M.; Sibley, S.D.; Pecotte, J.; Rice, K.; Weny, G.; Tumukunde, A.; Hyeroba, D.; Greene, J.;
Correll, M.; et al. Two novel simian arteriviruses in captive and wild baboons (Papio spp.). J. Virol. 2014, 88,
13231–13239. [CrossRef]
21. BioProject. SWBV Sequencing from Macaques and Baboons at SNPRC. Accession number: PRJNA483240.
Available online: https://www.ncbi.nlm.nih.gov/bioproject/483240 (accessed on 7 December 2018).
22. Joint Genome Institute. BBMap Guide. Available online: https://jgi.doe.gov/data-and-tools/bbtools/bb-
tools-user-guide/bbmap-guide/ (accessed on 7 December 2018).
23. SnpEff Genomic Variant Annotations and Functional Effect Prediction Toolbox. Available online: http:
//snpeff.sourceforge.net/ (accessed on 7 December 2018).
Viruses 2018, 10, 701 15 of 15
24. University of Wisconsin-Madison AIDS Vaccine Research Laboratory. Non-pathogenic Infection of Macaques
and Baboons with a Baboon Arterivirus. Available online: https://dholk.primate.wisc.edu/project/dho/
public/manuscripts/201808-SNPRC-SWBV/begin.view? (accessed on 7 December 2018).
25. Dokland, T. The structural biology of PRRSV. Virus Res. 2010, 154, 86–97. [CrossRef] [PubMed]
26. Gravell, M.; Palmer, A.E.; Rodriguez, M.; London, W.T.; Hamilton, R.S. Method to detect asymptomatic
carriers of simian hemorrhagic fever virus. Lab. Anim. Sci. 1980, 30, 988–991. [PubMed]
27. Bailey, A.L.; Lauck, M.; Weiler, A.; Sibley, S.D.; Dinis, J.M.; Bergman, Z.; Nelson, C.W.; Correll, M.; Gleicher, M.;
Hyeroba, D.; et al. High genetic diversity and adaptive potential of two simian hemorrhagic fever viruses in
a wild primate population. PLoS ONE 2014, 9, e90714. [CrossRef] [PubMed]
28. Lauck, M.; Switzer, W.M.; Sibley, S.D.; Hyeroba, D.; Tumukunde, A.; Weny, G.; Taylor, B.; Shankar, A.;
Ting, N.; Chapman, C.A.; et al. Discovery and full genome characterization of two highly divergent simian
immunodeficiency viruses infecting black-and-white colobus monkeys (Colobus guereza) in Kibale National
Park, Uganda. Retrovirology 2013, 10, 107. [CrossRef] [PubMed]
29. Lauck, M.; Sibley, S.D.; Hyeroba, D.; Tumukunde, A.; Weny, G.; Chapman, C.A.; Ting, N.; Switzer, W.M.;
Kuhn, J.H.; Friedrich, T.C.; et al. Exceptional simian hemorrhagic Fever virus diversity in a wild african
primate community. J. Virol. 2013, 87, 688–691. [CrossRef] [PubMed]
30. Gravell, M.; London, W.T.; Rodriguez, M.; Palmer, A.E.; Hamilton, R.S.; Curfman, B.L. Studies on simian
hemorrhagic fever virus infection of patas monkeys - I. Serology. In The Comparative Pathology of Zoo Animals
(the Symposia of the National Zoological Park); Montali, R.J., Migaki, G., Eds.; Smithsonian Institution Press:
Washington, DC, USA, 1980; pp. 167–170.
31. Gravell, M.; London, W.T.; Leon, M.E.; Palmer, A.E.; Hamilton, R.S. Differences among isolates of simian
hemorrhagic fever (SHF) virus. Proc. Soc. Exp. Biol. Med. (N. Y.) 1986, 181, 112–119. [CrossRef]
32. Gravell, M.; London, W.T.; Leon, M.; Palmer, A.E.; Hamilton, R.S. Elimination of persistent simian
hemorrhagic fever (SHF) virus infection in patas monkeys. Proc. Soc. Exp. Biol. Med. (N. Y.) 1986,
181, 219–225. [CrossRef]
33. Balasuriya, U.B.; Patton, J.F.; Rossitto, P.V.; Timoney, P.J.; McCollum, W.H.; MacLachlan, N.J. Neutralization
determinants of laboratory strains and field isolates of equine arteritis virus: Identification of four
neutralization sites in the amino-terminal ectodomain of the G(L) envelope glycoprotein. Virology 1997, 232,
114–128. [CrossRef]
34. Plagemann, P.G. Complexity of the single linear neutralization epitope of the mouse arterivirus lactate
dehydrogenase-elevating virus. Virology 2001, 290, 11–20. [CrossRef]
35. Plagemann, P.G.W.; Rowland, R.R.R.; Faaberg, K.S. The primary neutralization epitope of porcine respiratory
and reproductive syndrome virus strain VR-2332 is located in the middle of the GP5 ectodomain. Arch. Virol.
2002, 147, 2327–2347. [CrossRef]
36. Plagemann, P.G.W. The primary GP5 neutralization epitope of North American isolates of porcine
reproductive and respiratory syndrome virus. Vet. Immunol. Immunopathol. 2004, 102, 263–275. [CrossRef]
[PubMed]
37. Ostrowski, M.; Galeota, J.A.; Jar, A.M.; Platt, K.B.; Osorio, F.A.; Lopez, O.J. Identification of neutralizing
and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain.
J. Virol. 2002, 76, 4241–4250. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
